

■ **Monthly ibandronic acid* may be as effective as daily ibandronic acid in postmenopausal osteoporosis**, according to results from the phase III MOBILE** study. In this multinational trial, postmenopausal women were randomised to treatment with monthly oral ibandronic acid [Boniva], 100mg or 150mg on a single day, or 50mg on two consecutive days, or daily oral ibandronic acid 2.5mg, for 2 years. At 1 year's follow-up, all monthly regimens were at least as effective as the daily regimen at increasing lumbar spine bone mineral density. Preliminary safety evaluation suggested that all regimens were well tolerated.

* Roche, GlaxoSmithKline; registered for postmenopausal osteoporosis treatment and prevention in the US; preregistration in the EU

** Monthly Oral Ibandronate in Ladies

Roche, et al. New Phase III Study Successfully Shows Effect of Oral Monthly Boniva in Management of Osteoporosis. Media Release : 13 Jan 2004.
Available from: URL: <http://www.rocheusa.com> 809030154